Sign In
Buy RDHL
$1.00
-0.0100 (-0.99%)
At Close: Jun 03, 2026
RedHill (RDHL) to Begin Study on Second Coronavirus Candidate
12:16pm, Wednesday, 18'th Nov 2020
The FDA clears RedHill's (RDHL) IND filing for a phase II/III study on its second coronavirus candidate RHB-107 to treat patients with symptomatic COVID-19 who do not require hospitalization.
RedHill Biopharma Completes Enrollment for COVID-19 U.S. Phase 2 Study with Opaganib - Data Expected in the Coming Weeks
10:13am, Monday, 16'th Nov 2020
TEL AVIV, Israel and RALEIGH, NC, Nov. 16, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the U.S.
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2020 Results - Earnings Call Transcript
06:28pm, Thursday, 12'th Nov 2020
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q3 2020 Results - Earnings Call Transcript
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
10:30am, Wednesday, 04'th Nov 2020
Notice of Allowance received for combination of RedHill's novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP prot
H. pylori e radication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial , with antibiotic resistance a contributing factor . D espite declining e
